NDAINJECTIONSOLUTION
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIVFLOZA (nedosiran) is an oligonucleotide injection approved for primary hyperoxaluria, a rare genetic disorder causing excessive oxalate production and kidney damage. It works by reducing hepatic oxalate synthesis through RNA-based mechanism. The drug addresses a severe unmet need in a patient population with limited treatment options.
Growth12.4 years to LOE
Early-stage growth product with significant commercial runway; brand team likely small but expanding as market awareness increases.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
Started Feb 2022
27 enrolled
Primary HyperoxaluriaPrimary Hyperoxaluria Type 1Primary Hyperoxaluria Type 2+1 more
Treatment of Primary Hyperoxaluria Type 1 With Nedosiran
Primary Hyperoxaluria Type 1 (PH1)
Career Relevance
RIVFLOZA offers career growth in a rare disease specialty with high unmet need and limited competition; roles emphasize payer education, physician engagement, and patient access in a niche but expanding market. The oligonucleotide modality and Novo Nordisk's scale provide exposure to cutting-edge RNA technology and biosimilar-adjacent commercial strategies.
Worked on RIVFLOZA at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.